Abstract: The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.
Type:
Grant
Filed:
March 9, 2007
Date of Patent:
July 12, 2011
Assignee:
Tibotec-Virco Virology BVBA
Inventors:
Kenneth Alan Simmen, Tse-I Lin, Oliver Lenz, Dominique Louis Nestor Ghislain Surleraux, Pierre Jean-Marie Bernard Raboisson
Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.
Type:
Grant
Filed:
May 30, 2000
Date of Patent:
February 24, 2009
Assignee:
Tibotec-Virco Virology BVBA
Inventors:
Kurt Hertogs, Brendan Larder, Rudi Pauwels